SCHEMBL19260550

SCHEMBL19260550

COc1cc2c(NCCCO)c3ccccc3nc2cc1OCCCN1CCCC1

nearest known ligand 0.59

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
KMT5A Q9NQR1 3/20 0.59
HRH3 Q9Y5N1 1/20 0.58
EHMT2 Q96KQ7 11/20 0.55
DNMT1 P26358 3/20 0.55
EHMT1 Q9H9B1 6/20 0.54
TLR9 Q9NR96 2/20 0.54
TLR7 Q9NYK1 2/20 0.54
POLB P06746 1/20 0.51
RAD52 P43351 1/20 0.51
SPIN1 Q9Y657 1/20 0.51
NSD2 O96028 1/20 0.50
SLC2A1 P11166 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19260546 0.95 EHMT2 (0.60) KMT5AHRH3EHMT2DNMT1EHMT1
Trifluoroacetic Acid SCHEMBL19260602 0.93 KMT5A (0.53) KMT5AHRH3EHMT2DNMT1EHMT1
Trifluoroacetic Acid SCHEMBL19260773 0.89 EHMT2 (0.54) KMT5AHRH3EHMT2DNMT1EHMT1
SCHEMBL19260800 0.89 HRH3 (0.55) HRH3EHMT2DNMT1EHMT1TLR9
SCHEMBL19260809 0.89 HRH3 (0.53) KMT5AHRH3EHMT2DNMT1EHMT1
SCHEMBL19260562 0.88 EHMT2 (0.54) HRH3EHMT2DNMT1EHMT1TLR9
SCHEMBL19260597 0.87 EHMT2 (0.67) HRH3EHMT2DNMT1EHMT1TLR9
SCHEMBL19260688 0.87 EHMT2 (0.56) EHMT2DNMT1EHMT1TLR9TLR7
SCHEMBL19260604 0.87 EHMT2 (0.52) KMT5AHRH3EHMT2DNMT1EHMT1
SCHEMBL19260577 0.86 EHMT2 (0.59) EHMT2DNMT1EHMT1TLR9TLR7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11254651-B2 Histone methyltransferase inhibitors GLOBAL BLOOD THERAPEUTICS, INC. (US) 2022-02-22 US claimed
EP-3416963-B1 HISTONE METHYLTRANSFERASE INHIBITORS GLOBAL BLOOD THERAPEUTICS INC (US) 2021-07-28 EP claimed
US-20190047981-A1 HISTONE METHYLTRANSFERASE INHIBITORS GLOBAL BLOOD THERAPEUTICS, INC. 2019-02-14 US claimed
US-11584734-B2 Tricyclic compounds as histone methyltransferase inhibitors GLOBAL BLOOD THERAPEUTICS, INC. (US) 2023-02-21 US disclosed
US-11254651-B2 Histone methyltransferase inhibitors GLOBAL BLOOD THERAPEUTICS, INC. (US) 2022-02-22 US disclosed
US-20190047981-A1 HISTONE METHYLTRANSFERASE INHIBITORS GLOBAL BLOOD THERAPEUTICS, INC. 2019-02-14 US disclosed
EP-3416963-A1 HISTONE METHYLTRANSFERASE INHIBITORS Global Blood Therapeutics, Inc. (US) 2018-12-26 EP disclosed
WO-2017142947-A1 HISTONE METHYLTRANSFERASE INHIBITORS GLOBAL BLOOD THERAPEUTICS, INC. (US) 2017-08-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190047981-A1 HISTONE METHYLTRANSFERASE INHIBITORS EHMT1, EHMT2, BMI1 KMT5A 31/4885HRH3 1038/4885EHMT2 2/4885
US-11584734-B2 Tricyclic compounds as histone methyltransferase inhibitors EHMT1, EHMT2, BMI1 KMT5A 37/4885HRH3 1063/4885EHMT2 2/4885
US-11254651-B2 Histone methyltransferase inhibitors EHMT1, EHMT2, BMI1 KMT5A 31/4885HRH3 1038/4885EHMT2 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.